{"id":"fluticasone-propionate-cream-0-05","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin atrophy"},{"rate":null,"effect":"Striae"},{"rate":null,"effect":"Telangiectasia"},{"rate":null,"effect":"Local irritation or burning"},{"rate":null,"effect":"Folliculitis"}]},"_chembl":{"chemblId":"CHEMBL1201396","moleculeType":"Small molecule","molecularWeight":"444.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluticasone propionate binds to glucocorticoid receptors in skin cells, inhibiting the production of pro-inflammatory cytokines and mediators. This reduces inflammation, itching, and erythema characteristic of inflammatory skin conditions. The 0.05% cream formulation provides moderate potency for localized dermatological use.","oneSentence":"Fluticasone propionate is a topical corticosteroid that suppresses local inflammatory and immune responses in the skin.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:30:38.329Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and pruritic dermatoses responsive to topical corticosteroids"},{"name":"Eczema, psoriasis, and other inflammatory skin conditions"}]},"trialDetails":[{"nctId":"NCT03742414","phase":"PHASE2","title":"Seal, Stopping Eczema and Allergy Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kari Nadeau, MD, PhD","startDate":"2021-06-30","conditions":"Eczema, Infantile, Eczema, Atopic Dermatitis Eczema","enrollment":398},{"nctId":"NCT00763529","phase":"PHASE4","title":"Elocon vs Fluticasone in Localized Psoriasis (P03197)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-01-01","conditions":"Psoriasis","enrollment":245},{"nctId":"NCT04706559","phase":"NA","title":"Efficacy of Oral Supplementation of Probiotics in Children With Atopic Dermatitis","status":"COMPLETED","sponsor":"B.P. Koirala Institute of Health Sciences","startDate":"2021-01-03","conditions":"Atopic Dermatitis","enrollment":98},{"nctId":"NCT00803465","phase":"","title":"Randomized Study to Compare the Bioequivalence of Two Fluticasone Propionate 0.05% Topical Creams","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2003-04","conditions":"Healthy","enrollment":115},{"nctId":"NCT01915914","phase":"PHASE4","title":"A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Fluticasone Propionate 0.05% Cream (Twice Per Week) in Reducing the Risk of Relapse When Added to Regular Daily Moisturization Using PHYSIOGEL Lotion in Paediatric Subjects With Stabilized Atopic Dermatitis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-12-23","conditions":"Skin Diseases","enrollment":107},{"nctId":"NCT02290717","phase":"NA","title":"Fractional Laser in Combination With UVB Therapy in Vitiligo Patients","status":"WITHDRAWN","sponsor":"Netherlands Institute for Pigment Disorders","startDate":"2015-05","conditions":"Vitiligo","enrollment":""},{"nctId":"NCT01772056","phase":"PHASE3","title":"Efficacy Study of Topical Twice Weekly Fluticasone Treatment to Reduce Relapse in Atopic Dermatitis in Children","status":"TERMINATED","sponsor":"Elena Rubio Gomis","startDate":"2009-12","conditions":"Dermatitis, Atopic","enrollment":54},{"nctId":"NCT01246921","phase":"PHASE4","title":"Effect of Fluticasone Proprionate 0.05% on Narrow Band UV-B in Active Vitiligo","status":"UNKNOWN","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2009-09","conditions":"Patients With Active Non-segmental Vitiligo., Evaluation of the Efficacy of UVB and Fluticason Proprionate 0.05%, Cream Compared to NB-UVB Alone in Patients With Non-segmental Vitiligo","enrollment":50},{"nctId":"NCT00119158","phase":"PHASE4","title":"Combination Therapy for Atopic Dermatitis","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2004-10","conditions":"Atopic Dermatitis","enrollment":90},{"nctId":"NCT00616538","phase":"PHASE4","title":"Epiceram™ Device Versus Mid-Strength Topical Steroid (Fluticasone Propionate 0.05%) for Treatment of Atopic Dermatitis","status":"COMPLETED","sponsor":"Ceragenix Pharmaceuticals","startDate":"2006-12","conditions":"Atopic Dermatitis","enrollment":121}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Fluticasone Propionate Cream 0.05%","genericName":"Fluticasone Propionate Cream 0.05%","companyName":"Netherlands Institute for Pigment Disorders","companyId":"netherlands-institute-for-pigment-disorders","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fluticasone propionate is a topical corticosteroid that suppresses local inflammatory and immune responses in the skin. Used for Inflammatory and pruritic dermatoses responsive to topical corticosteroids, Eczema, psoriasis, and other inflammatory skin conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}